Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M75.2Revenue $M18.1Net Margin (%)-291.0Z-Score-10.4
Enterprise Value $M43.5EPS $-1.0Operating Margin %-278.4F-Score2
P/E(ttm))0Cash Flow Per Share $0.8Pre-tax Margin (%)-291.0Higher ROA y-yY
Price/Book3.610-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsN
Price/Sales3.95-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %0ROA % (ttm)-49.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-111.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M52.1ROI % (ttm)-74.6Gross Margin Increase y-yN

Gurus Latest Trades with AVEO

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AVEOSeth Klarman 2014-12-31 Sold Out -0.07%$0.65 - $1.17
($0.91)
$ 1.4437%Sold Out0
AVEOSeth Klarman 2013-06-30 Reduce-0.26%$2.34 - $8.27
($4.27)
$ 1.44-197%Reduce -21.90%3,829,350
AVEOGeorge Soros 2011-12-31 Sold Out -0.0031%$14.53 - $17.35
($8.42)
$ 1.44-485%Sold Out0
AVEOSeth Klarman 2011-09-30 Add0.29%$15.12 - $20.77
($17.66)
$ 1.44-1126%Add 12.79%5,000,000
AVEOGeorge Soros 2011-09-30 Reduce-0.04%$15.12 - $20.77
($17.66)
$ 1.44-1126%Reduce -92.80%11,600
AVEOSeth Klarman 2011-06-30 Add0.78%$13.06 - $20.66
($16.79)
$ 1.44-1066%Add 25.76%4,433,010
AVEOGeorge Soros 2011-06-30 Buy 0.05%$13.06 - $20.66
($16.79)
$ 1.44-1066%New holding161,000
AVEOSeth Klarman 2011-03-31 Add1.15%$13.15 - $15.02
($14.21)
$ 1.44-887%Add 76.25%3,525,000
AVEOSeth Klarman 2010-12-31 Buy 1.68%$13.84 - $17.41
($15.14)
$ 1.44-951%New holding2,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AVEO is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


AVEO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dallas Matthew DVP, Finance 2015-01-16Sell3,075$0.8265.85view
BAILEY MICHAEL PPresident & CEO 2015-01-07Sell4,484$0.870view
Dallas Matthew DVP, Finance 2015-01-07Sell519$0.870view
Vittiglio JosephSVP, General Counsel 2015-01-07Sell4,484$0.870view
Gyuris JenoSVP, Chief Scientific Officer 2015-01-07Sell4,484$0.870view
Dallas Matthew DVP, Finance 2014-07-01Sell0$070view
BAILEY MICHAEL PChief Business Officer 2014-01-30Sell5,430$1.64-17.07view
Vittiglio JosephSVP, General Counsel 2014-01-30Sell5,430$1.64-17.07view
Gyuris JenoSVP, Chief Scientific Officer 2014-01-30Sell5,430$1.64-17.07view
Slichenmyer WilliamChief Medical Officer 2014-01-30Sell5,430$1.64-17.07view

Press Releases about AVEO :

    Quarterly/Annual Reports about AVEO:

    News about AVEO:

    Articles On GuruFocus.com
    Wild Card Wonders, Shopping for 52-Week Lows Sep 29 2013 
    Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
    comment on AVEO Mar 16 2013 
    comment on AVEO Mar 16 2013 
    Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
    Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
    Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 15 2011 
    AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
    Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
    Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

    More From Other Websites
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 24 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events Mar 19 2015
    AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade Mar 09 2015
    AVEO Up on Pipeline News, Q4 Loss Narrower than Expected - Analyst Blog Mar 09 2015
    10-K for AVEO Pharmaceuticals, Inc. Mar 08 2015
    AVEO Pharmaceuticals Soars On Phase II Results Vs. Avastin Mar 06 2015
    AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib... Mar 06 2015
    AVEO Oncology Reports Full Year 2014 Financial Results Mar 06 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Mar 06 2015
    AVEO Oncology Reports Full Year 2014 Financial Results Mar 06 2015
    AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib... Mar 06 2015
    Regulators Want Drug Companies to Be Honest About FDA Mar 04 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 27 2015
    AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
    AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
    Aveo Pharmaceuticals loses position in The Baupost Group Feb 11 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 23 2015
    AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 14 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 13 2015
    AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 12 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK